Pharmasset publicly offers $92.8 million in stock
Early stage drug developer Pharmasset Inc. said Thursday it is publicly offering $92.8 million in common stock.
Biotechnology company ZymoGenetics Inc. said Thursday it is publicly offering about $79 million in common stock and boosting the number of shares, increasing the number it said it would offer.